Compare AZTA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZTA | TNGX |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | AZTA | TNGX |
|---|---|---|
| Price | $20.15 | $19.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $42.60 | $18.75 |
| AVG Volume (30 Days) | 826.8K | ★ 3.5M |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.52 | 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $593,821,000.00 | $62,384,000.00 |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $20.22 | $1.04 |
| 52 Week High | $41.73 | $19.55 |
| Indicator | AZTA | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 21.98 | 75.56 |
| Support Level | N/A | $5.98 |
| Resistance Level | $32.18 | N/A |
| Average True Range (ATR) | 1.15 | 1.26 |
| MACD | -0.03 | 0.34 |
| Stochastic Oscillator | 0.08 | 91.12 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.